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Introduction: Achievement of early therapeutic anticoagulation with unfractionated heparin (UFH) is
associated with improved outcomes in thromboembolic disease. Weight based UFH expedites time to
therapeutic anticoagulation. Treatment with UFH is challenging in surgical patients due to their high
propensity for bleeding. We sought to test the hypothesis that an initial weight based UFH infusion in
surgical patients increases the percentage of patients who achieve early therapeutic anticoagulation
without increasing the risk of hemorrhagic events. Methods: Using a non-concurrent retrospective
cohort study design, adult surgical patients receiving UFH for venous thromboembolism (VTE) at a
tertiary care center were included. Two groups were identiﬁed: the weight based (WB) and the under-
dosed (UD) heparin groups. For our primary outcome, we compared percentage of patients in each group
that achieved a therapeutic PTT within 24 h. Secondary outcomes included the incidence of supra-
therapeutic PTT levels, hemorrhagic events, and complications associated with VTE. Results: 73 subjects
met study criteria, which included 8 subjects in the WB group and 65 in the UD group. The demographic,
baseline laboratory, admitting service and type of VTE were similar between the 2 groups. The per-
centages of WB and UD subjects who achieved a therapeutic PTT within 24 h were 75% and 28%,
respectively (p < 0.01). There was no difference in the incidence of supratherapeutic PTT or hemorrhagic
events. Conclusion: Surgical patients who received an initial weight based UFH infusion achieved earlier
therapeutic anticoagulation compared to under-dosed UFH without increasing the occurrence of
supratherapeutic PTT levels or hemorrhagic events.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Massachusetts General Hos-
).
by Elsevier Ltd. All rights reserved1. Introduction
Hospitalized patients in the post-operative state are among
those at highest risk for venous thromboembolism (VTE), the most
common preventable cause of hospital mortality [1]. Without
chemoprophylaxis, the risk of deep vein thrombosis (DVT) in sur-
gical patients with major trauma and spinal cord injury exceeds.
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population can be challenging given the increased risk of bleeding
from surgery and trauma. These factors are further ampliﬁed in
surgical patients admitted to the intensive care unit (ICU) due to
coexisting coagulopathy, thrombocytopenia, and presence of renal
dysfunction [3].
The standard treatment options for VTE in the acute setting
include unfractionated heparin (UFH) or low molecular weight
heparin (LMWH). Use of UFH in surgical patients is more advan-
tageous in the peri-operative and peri-procedural setting due to its
short half-life, the availability of a reversal agent, and its extra-renal
elimination [4]. Weight based UFH treatment initiated with a
loading dose of 80 units/kg followed by an infusion at 18 units/kg
per hour has been shown to expedite the time to achieve goal
activated partial thromboplastin time (PTT) and reduce recurrent
VTE [5,6]. Additionally, achievement of goal PTT within 24 h in
patients with acute pulmonary embolism (PE) is associated with a
66% reduction in 30-day mortality [7].
Several risk factors for bleeding related to UFH treatment have
been outlined [8]. One of these risk factors includes the intensity of
UFH dosing [9]. Limited data is available describing the beneﬁts and
risks of weight-based UFH dosing in surgical patients. We sought to
assess and compare the effectiveness and safety of weight based
(WB) versus under-dosed (UD) UFH infusion in surgical patients
with VTE.
2. Material and methods
2.1. Patient population and data collection
Using the Partners Healthcare System Research Patient Data
Registry (RPDR), a comprehensive clinical and administrative
database at our tertiary academic medical center, we identiﬁed all
patients aged 18 years or older with ICD9-CM diagnoses of DVT and
PE who received an UFH infusion for at least 24 h from June 1, 2010
toMay 31, 2011. DVT and PE diagnoses were conﬁrmed by review of
ultrasound or computed tomography, respectively.
Patient demographics, co-morbidities, pre- and post-infusion
laboratory values, and VTE-related complications were collected
from medical records. The following data were additionally
captured: dates of hospital and ICU admission, time of initiation
and discontinuation of UFH, and dates of ICU and hospital
discharge. The admitting surgical service and type of surgery per-
formed were also recorded from the operative report. The bolus
dose, initial rate of infusion, and duration of UFH administration
were obtained from the electronic medical record. Concurrent
blood product administration and the simultaneous use of medi-
cations that could potentiate bleeding such as clopidogrel, aspirin,
non-steroidal anti-inﬂammatory drugs, and warfarin were also
recorded.
2.2. WB vs. UD groups
The standard template for VTE treatment at our institution
recommends initiating UFH with a loading dose of 80 units/kg
followed by a rate of 18 units/kg per hour, based on the nomogram
established by Raschke et al. [5]. UFH infusions were titrated using
a standardized sliding scale to a goal PTT between 60 and 84 s. Our
standard lab monitoring protocol is to draw PTT prior to UFH
initiation, 6 h after initiation of therapy, and 6 h after any dosage
adjustment. Once infusion rates were stable and patients were
maintained in the therapeutic range, PTT was monitored twice
daily.
In our study, the WB group included patients who received an
initial UFH infusion at a rate of at least 18 units/kg per hour roundedto the nearest 50 units based on patient's actual body weight. The
UD group included patients who received an initial UFH infusion
less than 18 units/kg per hour.
2.3. Primary and secondary endpoints
The primary endpoint of the study is the percentage of patients
who achieved a therapeutic PTT within 24 h. Secondary endpoints
included the incidence of supratherapeutic PTT levels, the inci-
dence of hemorrhagic events, and complications associated with
VTE that occurred during each subjects’ hospital admission.
Hemorrhagic events were deﬁned as acute non-operative blood
loss of at least 2 g/dL of hemoglobin that required both cessation of
UFH and blood transfusion. Non-operative bleeding was deﬁned as
any hemorrhagic event that occurred 24 h after the operation. If the
UFH infusionwas held at least 6 h before and 24 h after surgery and
the patient experienced a hemorrhagic event within 24 h of the
operation, this was deemed to be due to operative bleeding. VTE
complications included DVT conversion to PE, stroke, patient
transfer to an ICU, cardiac arrest, and death.
2.4. Statistical analysis
Data analysis was performed using Microsoft Ofﬁce Excel 2011
(Microsoft Corporation, Redmond, WA, USA) and STATA 13 (Stata-
Corp. 2013. Stata Statistical Software: Release 13. College Station,
TX: StataCorp LP). Demographic data were presented as
mean ± standard deviation for continuous variables. Statistical
signiﬁcance for continuous variables were analyzed using a 2 in-
dependent sample t-test and categorical variables were calculated
using a Fisher's exact test. Ordinal data was analyzed with the
WilcoxoneManneWhitney test. An alpha-error of 0.05 or less was
considered to be statistically signiﬁcant. The modiﬁed Thompson
tau techniquewas used to detect outliers for UFH duration and total
administered packed red blood cells (pRBC).
This retrospective non-concurrent caseecontrol study was
approved by the Partners Institutional Review Board (IRB number:
2013P001282, MGH).
3. Results
During the study time period, 590 patients requiring UFH were
assessed, of which 73 met the inclusion criteria. Of the 517 patients
excluded, 483 were initiated on UFH for a non-VTE indication, 17
received UFH less than or equal to 24 h, 16 were non-surgical pa-
tients and 1 was identiﬁed as an outlier. Eight subjects received
weight based UFH compared to 65 subjects in the UD group. Patient
demographics of each group are described in Table 1. The 2 groups
were equal at baseline with the exception of subjects in the UD
group having a signiﬁcantly higher mean body weight at 90 kg
compared to 65 kg in the WB group (p ¼ 0.02).
Twenty-ﬁve percent of subjects in each group received an initial
UFH bolus dose (p¼ 1.0). Of the subjects who received a bolus dose,
2 subjects in each group received aweight based bolus (p¼ 0.06). In
these subjects, the mean time to achieve target PTT was
28.9 ± 15.9 h compared to 47.2 ± 38.6 h (p ¼ 0.38) in subjects who
received an under-dosed bolus and 50.5 ± 47.2 h in the non-bolused
subjects (p¼ 0.37). Fifty percent of subjects whowere administered
an appropriate weight based bolus developed a supratherapeutic
ﬁrst PTT compared to 7% of subjects who had an under-dosed bolus
(p ¼ 0.04) or no bolus (p < 0.01).
The mean initial infusion rate in the WB group was
21.4± 4.47 units/kg compared to 8.94 ± 3.54 units/kg (p< 0.01). The
mean initial PTT in the WB group was 61.4.5 ± 37.2 s vs. 44.1 ± 26.3
in the UD group (p¼ 0.09). The percentage of subjects in each group
Table 2
Concurrent anticoagulants and amount of blood products administered while
receiving UFH.
Weight based
(n ¼ 8)
Under-dosed
(n ¼ 65)
P value
Concurrent anticoagulants, no. (%)
Clopidogrel 1 (13) 7 (11) 1.0
High dose aspirin (>81 mg) 2 (25) 22 (34) 1.0
Low dose aspirin (81 mg) 2 (25) 19 (29) 1.0
NSAIDs 0 3 (5) 1.0
Warfarin 5 (63) 42 (65) 1.0
Blood products, Mean ± SD
Total FFP 5.13 ± 11.8 1.52 ± 7.40 0.23
Total pRBCs 4 ± 5.53 3.37 ± 5.75 0.77
NSAIDs, non-steroidal anti-inﬂammatory drugs; FFP, fresh frozen plasma; pRBCs,
packed red blood cells.
Table 1
Patient demographics.
Weight based
(n ¼ 8)
Under-dosed
(n ¼ 65)
P value
Demographics,
Mean ± SD
Age 66.3 ± 15.1 years 60.0 ± 19.0 years 0.30
Weight 65.0 ± 21.8 kg 90.0 ± 27.7 kg 0.02
BMI 24.1 ± 4.81 29.7 ± 8.65 0.08
APACHE II 26.8 ± 8.99 34 ± 4.24 0.12
Charlson
comorbidity
index
3 ± 3 2 ± 2 0.08
Male sex, no. (%) 3 (38) 44 (68) 0.12
ICU admission,
no. (%)
7 (88) 48 (74) 0.67
Laboratory ﬁndings,
Mean ± SD
Creatinine 1.05 mg/dL ± 0.81 1.32 mg/dL ± 1.22 0.55
International
normalized ratio
1.15 ± 0.18 1.20 ± 0.43 0.73
Alanine
aminotransferase
26 U/L ± 27.2 87.8 U/L ± 259 0.53
Aspartate
aminotransferase
39.6 U/L ± 38.6 152 U/L ± 562 0.60
Lactate 1.64 mmol/L ± 0.50 3.04 mmol/L ± 2.2 0.17
Base excess 1.15 ± 1.47 1.19 ± 3.90 0.15
Admitting surgical
service, no. (%)
Cardiac 1 (13) 15 (23) 0.16
Gastrointestinal 1 (13) 3 (5)
Neurology 3 (38) 9 (14)
Orthopedic 1 (13) 8 (12)
Thoracic 0 6 (9)
Trauma 1 (13) 9 (14)
Urology 1 (13) 1 (2)
Vascular 0 14 (22)
Type of VTE, no. (%)
DVT 4 (50) 35 (54) 0.78
PE 3 (38) 16 (25)
DVT and PE 1 (13) 14 (22)
APACHE-II, acute physiology and chronic health evaluation; ICU, intensive care unit;
DVT, deep vein thrombosis; PE, pulmonary embolism.
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(p < 0.01). The WB group received therapy for a mean duration of
78 ± 126 h vs. 62 ± 88 h (p ¼ 0.68) and number of supratherapeutic
PTTs were 3 ± 6 vs. 3 ± 4 during therapy (p ¼ 0.87). The percentage
of subjects who had a supratherapeutic PTT at any time while
receiving UFH was 63% in the WB group and 65% in UD group
(p ¼ 1.0). The mean number of interruptions and duration neces-
sary to hold UFH was similar between groups.
There was no signiﬁcant difference between percentage of
subjects receiving concurrent medications that could potentiate
bleeding or in the amount of blood products administered while
receiving UFH between the 2 groups as shown in Table 2. Thirteen
percent of subjects in the WB group experienced a hemorrhagic
event versus 12 percent in the UD group (p ¼ 1.0). None of the
subjects who had a weight based bolus developed a hemorrhagic
event. Of the subjects who had a hemorrhagic event, 2 subjects
were receiving concomitant anticoagulants and both were in the
UD group. The PTTand platelet count of the subject in theWB group
who had a hemorrhagic event was 108 s and 408 109/L, respec-
tively. The subjects who received UD heparin who experienced a
hemorrhagic event had a mean PTT of 71 ± 10 s and platelet count
of 160 ± 44109/L. Themean time of initiating UFH in relationship to
surgery was 4 ± 6 days in the WB group compared to 3 ± 7 days in
the UD group (p ¼ 0.51). There were no signiﬁcant differences be-
tween individual VTE complications (p ¼ 1.0). Twenty-ﬁve percent
of subjects in both groups experienced an overall complication
(p ¼ 1.0).4. Discussion
Based on our results, we found that an initial infusion based on
patient's weight is associatedwith a signiﬁcantly higher percentage
of subjects achieving a therapeutic PTT within 24 h. This approach
was not associated with a greater number of supratherapeutic or
increased risk of hemorrhagic events. Subjects who received a
weight based bolus were more likely to develop an initial supra-
therapeutic PTT compared to subjects who were administered an
under-dosed bolus or no bolus, but this did not appear to increase
bleeding risk.
The beneﬁts of early anticoagulation in VTE have been well
described and commonly accepted such that guidelines now
recommend initiating anticoagulation prior to diagnostic testing if
the clinical suspicion for DVT or PE is high [10]. The primary goal of
initiating UFH treatment during VTE is to prevent clot propagation
and decrease the risk of further complications [3]. Previous studies
demonstrated that achieving a therapeutic PTT within 24 h led to a
signiﬁcant decrease inVTE reoccurrence [5,11]. Furthermore, there is
an association between earlier administration of UFH in PE and a
signiﬁcant reduction in 30-day mortality and lower in-hospital
mortality [7].
Studies have shown that patients randomized to weight-based
UFH more rapidly and reliably achieve a therapeutic PTT
compared to non-weight based UFH [5,6,11]. Subsequently, weight-
based UFH for VTE is endorsed by the recent antithrombotic
guidelines [10]. Despite these recommendations, clinicians may
deviate fromweight based dosing regimens if patients are obese or
deemed at high risk of bleeding. Our study found a high rate of
conservative dosing in surgical patients, given that only 25%
received an initial bolus dose and only 11% received a weight based
infusion. Among obese subjects, our data also suggests that clini-
cians are less inclined to use actual body weight for UFH dosing,
perhaps due to reluctance to administer doses much higher than
routinely used. This is consistent with a previous study that found
that 89.3% of boluses and 76.2% of initial continuous infusions were
under-dosed in patients with BMIs greater 30 [12].
One of the most difﬁcult challenges in managing anticoagulant
therapy is minimizing hemorrhagic complications requiring blood
transfusion or surgical intervention. Predictors of bleeding include
patient intrinsic factors, timing of post-procedural anticoagulation,
and aggressiveness of UFH therapy. Evidence has shown that co-
morbid conditions, such as recent surgery or trauma are impor-
tant risk factors for UFH induced bleeding. Furthermore, premature
re-initiation of therapeutic UFH, deﬁned as restarted within 24 h of
the procedure, is the strongest predictor of bleeding complications
[13]. The mean time of UFH initiation in our study was 3 ± 7 days
after surgery with no signiﬁcant time difference between groups.
We found that 13% of subjects had a hemorrhagic event in the WB
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pected based on their high-risk nature. Our results are consistent
with previous studies that found hemorrhagic events occurred
even when the anticoagulant response is in the therapeutic range
[14]. Furthermore, the incidence of hemorrhage events was com-
parable in both groups regardless of the intensity of UFH therapy.
However, these exploratory results should be interpreted with
caution, as the sample sizes are small and would represent an
underestimation of the true bleeding risk.
There are several limitations worth noting in our study. Fore-
most, this is a retrospective, single-center study with a relatively
small sample size that limits the generalization of our ﬁndings. Due
to the retrospective nature of our study, we relied on the
completeness of patients' medical records to collect data. We also
deﬁned our intervention group as subjects who received weight
based infusion alone instead of receiving both a weight based bolus
and infusion as recommended in the current antithrombotic
guidelines. Given that only 5% of patients received a weight based
bolus dose overall, this likely did not signiﬁcantly inﬂuence our
results. Despite loosening our criteria, appreciably more subjects in
the intervention group still achieved earlier anticoagulation, sug-
gesting that both interventions may not be required to meet this
goal. Another possible limitation is the frequency and consistency
with which PTTs were drawn. For example, the time to a thera-
peutic level could be affected if one of the groups used more
frequent monitoring or had better precision with timing PTT lab
draws. We also did not assess compliance with our institution's
UFH sliding scale titration protocol and therefore were unable to
determine if deviations from the protocol inﬂuenced time to ther-
apeutic goal in each group. Lastly, our evaluation of only inpatient
VTE complications limited our ability to assess efﬁcacy on longi-
tudinal outcomes such as VTE reoccurrence. Larger, prospective
studies are needed to validate the efﬁcacy and safety of weight-
based UFH dosing in surgical patients.
In conclusion, initial UFH infusions based on patient's weight is
associated with earlier achievement of goal PTT among surgical
patients and subjects who receivedweight based bolus dosingwere
more likely to develop a supratherapeutic ﬁrst PTT. However,
neither of these approaches appeared to increase bleeding risk. Our
data suggests that practitioners are hesitant to prescribe higher
than routinely used doses required for VTE treatment in heavier
surgical patients and therefore these patients are most susceptible
to being under-dosed.
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